InPedILD_trial_enrollment

Phase III InPedILD ™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung diseaseFirst-of-its-kind clinical trial in children and adolescents with fibrosing interstitial lung disease (ILD) initiated globallyThis new study builds on the Phase III INBUILD ® trial and approval of Ofev® in adult patients with fibrosing ILDs with a progressive phenotype1,2,3Global Phase III multicentre clinical trial is planned to be conducted in approximately 70 sites in 24 countries
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news